Orthofuse closed a £2.2 million (~US $3 million) seed round. This funding, led by a group of angel investors with participation from ACF investors, Cambridge Angels, and Empirical Ventures, supports the company’s development of 3D-printed implant systems that prioritize surgical ease of use and patient safety.
By leveraging advanced additive manufacturing techniques and novel implant architectures, the company seeks to create solutions designed to reduce the number of surgical steps while ensuring strong fixation.
A key focus is improving reversibility, allowing surgeons to adjust or reposition hardware without compromising surrounding tissue. This shift is particularly valuable in complex trauma cases where anatomy can be unpredictable and small adjustments have a major impact.
This investment will enable Orthofuse to advance its technical development, regulatory readiness, and strengthen partnerships as it prepares for early-stage clinical evaluations.
James Scott, Co-Founder and CEO, Orthofuse, said: “Modern surgical practice demands implant systems that reflect the realities of the operating room. Orthofuse is developing a technology designed to simplify procedures, giving surgeons greater flexibility and confidence. This investment enables us to accelerate progress toward setting a new standard for safety and efficiency in orthopaedic care.”
Orthofuse closed a £2.2 million (~US $3 million) seed round. This funding, led by a group of angel investors with participation from ACF investors, Cambridge Angels, and Empirical Ventures, supports the company's development of 3D-printed implant systems that prioritize surgical ease of use and patient safety.
By leveraging advanced additive...
Orthofuse closed a £2.2 million (~US $3 million) seed round. This funding, led by a group of angel investors with participation from ACF investors, Cambridge Angels, and Empirical Ventures, supports the company’s development of 3D-printed implant systems that prioritize surgical ease of use and patient safety.
By leveraging advanced additive manufacturing techniques and novel implant architectures, the company seeks to create solutions designed to reduce the number of surgical steps while ensuring strong fixation.
A key focus is improving reversibility, allowing surgeons to adjust or reposition hardware without compromising surrounding tissue. This shift is particularly valuable in complex trauma cases where anatomy can be unpredictable and small adjustments have a major impact.
This investment will enable Orthofuse to advance its technical development, regulatory readiness, and strengthen partnerships as it prepares for early-stage clinical evaluations.
James Scott, Co-Founder and CEO, Orthofuse, said: “Modern surgical practice demands implant systems that reflect the realities of the operating room. Orthofuse is developing a technology designed to simplify procedures, giving surgeons greater flexibility and confidence. This investment enables us to accelerate progress toward setting a new standard for safety and efficiency in orthopaedic care.”
Copy to clipboard 
